ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

JKN2403

A development code. Also written as “JKN2403 Tablets”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Joincare Pharmaceutical Group Industry.

Furthest: phase 2, since Jan 10, 20261 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Joincare Pharmaceutical Group Industry11 open or runningphase 2since Jan 10, 2026Jan 10, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 10, 2026First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT07351734 · 120 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07351734Pulmonary Disease, Chronic Obstructive · China2RecruitingSep 30, 2026120

How it is read

Names in the registry

  • “JKN2403 Tablets”, 1 entry

Codes read as this program: JKN2403.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.